#ClinicalTrial EAQ222CD/CostCOM, led by Gelareh Sadigh, MD of @UCIrvineHealth, is testing the effectiveness of cost communication & financial navigation in patients with cancer. If you have any newly diagnosed solid cancer, you may be able to participate. https://bit.ly/EAQ222CD
Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: http://bit.ly/indicate-trial #pcsm #ProstateCancerAware
The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study #LCSM #RWD #RWE
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).